Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Patients with acute myocardial infarction (AMI) often require emergency percutaneous coronary intervention (PCI).
• Perioperative antiplatelet therapy is crucial for managing these high-risk patients.
• Comparing the efficacy of ticagrelor and clopidogrel in this setting is essential.

Purpose of the Study:

• To compare the antiplatelet effects of ticagrelor versus clopidogrel in patients with AMI undergoing emergency PCI.
• To evaluate the impact of these antiplatelet agents on thrombelastogram (TEG) parameters and platelet aggregation.
• To assess the incidence of major adverse cardiac events (MACE) during the perioperative period.

Main Methods:

• A randomized controlled trial involving 120 patients with AMI undergoing emergency PCI.
• Patients received either ticagrelor (180 mg) or clopidogrel (300 mg) pre-PCI, both combined with aspirin.
• Thrombelastogram (TEG) and platelet aggregation were measured; MACE were recorded over 6 months.

Main Results:

• Ticagrelor group showed prolonged R and K values in TEG, indicating reduced platelet activation.
• The ticagrelor group exhibited lower α angle, MA, CI, MARAA, and MARADP values compared to the clopidogrel group (P<0.05).
• No significant differences were observed in the timing of medication, stent implantation, or dosages of heparin and tirofiban.

Conclusions:

• Ticagrelor significantly enhances antiplatelet effects in patients with AMI during perioperative emergency PCI.
• These findings suggest ticagrelor is a more effective option for perioperative antiplatelet therapy in this patient population.
• Improved antiplatelet activity with ticagrelor may contribute to better clinical outcomes in high-risk cardiovascular patients.